Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes

METHODS: 40 individuals with type 1 diabetes (average age of 44.7 ± 2.5 years) were randomized into four groups: (1) control (placebo), (2) empagliflozin 25 mg daily, (3) metformin 2000 mg daily, and (4) empagliflozin-metformin combination (25 mg and 2000 mg daily, respectively). At inclusion and af...

Descripción completa

Detalles Bibliográficos
Autores principales: Janić, Miodrag, Cankar, Matej, Šmid, Jan, France Štiglic, Alenka, Jerin, Aleš, Šabovič, Mišo, Janež, Andrej, Lunder, Mojca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130013/
https://www.ncbi.nlm.nih.gov/pubmed/35620570
http://dx.doi.org/10.1155/2022/6796470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130013/
https://www.ncbi.nlm.nih.gov/pubmed/35620570
http://dx.doi.org/10.1155/2022/6796470

Ejemplares similares